Cynata Therapeutics Ltd [ASX:CYP] reported a massive win late last night. Their Japanese benefactor, Fujifilm, is going to license their CYP-001 treatment.
Australian stem cell research company Cynata Therapeutics' share price tumbled 31.64% this morning, shedding 55 cents to trade at $1.22. This morning’s nosedive comes on the back of strong gains made since the beginning of December, climbing 84.5% to reach $1.79 — its highest price since October 2010.
Cynata Therapeutics Limited [ASX:CYP] ended 2018 on a strong note, posting a gain of 30% in the last two weeks of the year. The company’s stock value has increased by more than 124% over the past 12 months.